Parkinson disease and growth factors — is GDNF good enough?

Previous open-label trials testing glial cell line-derived neurotrophic factor (GDNF) family ligands in Parkinson disease have shown promising clinical effects. However, in placebo-controlled trials, the treatments have failed. A new randomized placebo-controlled trial of intraputamenal delivery of GDNF designed to resolve this conundrum has again failed to do just that.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Evans, J. R. & Barker, R. A. Neurotrophic factors as a therapeutic target for Parkinson’s disease. Expert Opin. Ther. Targets 12, 437–447 (2008).

    CAS  Article  Google Scholar 

  2. 2.

    Kordower, J. H. In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson’s disease. Ann. Neurol. 53 (Suppl. 3), 120–132 (2003).

    Article  Google Scholar 

  3. 3.

    Lang, A. E. et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459–466 (2006).

    CAS  Article  Google Scholar 

  4. 4.

    Lang, A. E. et al. GDNF in treatment of Parkinson’s disease: response to editorial. Lancet Neurol. 5, 200–202 (2006).

    Article  Google Scholar 

  5. 5.

    Warren Olanow, C. et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann. Neurol. 78, 248–257 (2015).

    CAS  Article  Google Scholar 

  6. 6.

    Whone, A. et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease. Brain 142, 512–525 (2019).

    Article  Google Scholar 

  7. 7.

    Whone, A. L. et al. Extended treatment with glial cell line-derived neurotrophic factor in Parkinson’s disease. J. Parkinsons Dis. (2019).

    Article  PubMed  Google Scholar 

  8. 8.

    Decressac, M. et al. α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci. Transl Med. 4, 163ra156 (2012).

    Article  Google Scholar 

  9. 9.

    Patel, N. K. et al. Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation. Neurology 81, 1176–1178 (2013).

    Article  Google Scholar 

  10. 10.

    Kordower, J. H. et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 136, 2419–2431 (2013).

    Article  Google Scholar 

Download references

Author information



Corresponding authors

Correspondence to Agnete Kirkeby or Roger A. Barker.

Ethics declarations

Competing interests

A.K. is the owner of the company Kirkeby Cell Therapy holding patents for the development of cell therapies for Parkinson disease (PD). A.K. and R.A.B. are consultants for Novo Nordisk A/S on the development of cell therapies for PD. R.A.B. also works as a consultant on cell-based therapies for Fujifilm Cellular Dynamics, Cellino and Living Cell Technologies.

Additional information

Related links

The Parkinson’s Drug Trial: A Miracle Cure?:

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kirkeby, A., Barker, R.A. Parkinson disease and growth factors — is GDNF good enough?. Nat Rev Neurol 15, 312–314 (2019).

Download citation

Further reading


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing